Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

Purpose

Post-transplant lymphoproliferative disorders (PTLD) differ clinically from lymphoma in the general (immunocompetent) population due to their higher incidence and their frequent association with Epstein-Barr virus. Previous clinical trials have shown their remarkably good response to rituximab as well as to chemotherapy.

The PTLD-1 trial demonstrated the efficacy and safety of sequential immunochemotherapy with 4 courses of rituximab IV followed by 4 cycles of CHOP chemotherapy. Compared to trials of rituximab
monotherapy in PTLD, median overall survival was extended from 2.4 to 6.5 years. Compared to previous trials of chemotherapy, complications were reduced. In addition, we noted that those patients who already had a good response to the first four cycles of rituximab did better overall than those who did not. As a consequence, the PTLD-1/3 trial introduced risk-stratification in sequential treatment according to the response to the first 4 courses of rituximab monotherapy. Those patients with a complete remission went on to receive four further courses of rituximab whereas those who did not received rituximab and CHOP chemotherapy. Interim results have demonstrated that it is safe to restrict chemotherapy treatment in this manner and thus established the concept of treatment stratification based on the response to rituximab.

The **PTLD-2** trial is the next step in the development of this strategy. Compared to the PTLD-1/3 trial, the key difference is the use of subcutaneous instead of intravenous rituximab application. Interim results from an ongoing trial of patients with follicular lymphoma (NCT01200758) have shown that subcutaneous administration results in increased blood levels and in non-inferior remission rates. Furthermore, the stratification strategy is refined based on observations from the previous PTLD-1 and PTLD1/3 trials: Risk groups are now defined not only based on response to rituximab therapy but also on the international prognostic index (IPI, a well-established lymphoma risk score) and the transplanted organ. The major advantage of this new stratification is an extended low-risk group that is eligible for subcutaneous rituximab monotherapy: Patients with a low risk of disease progression, defined as those who achieve a complete remission after the first four courses of subcutaneous rituximab monotherapy and those with an IPI of 0 to 2 who achieve a partial remission at interim staging, will go on with rituximab monotherapy. Patients with high IPI who achieve a partial remission, patients with stable disease at interim staging and non-thoracic transplant recipients with progressive disease at interim staging will be considered high risk. These patients will go on with 4 cycles of rituximab plus CHOP chemotherapy similar to the PTLD-1/3 protocol. Thoracic transplant recipients refractory to rituximab will be considered very high risk and will go on with rituximab subcutaneous plus alternating chemotherapy with CHOP and DHAOx.

The trial hypothesis is that the new protocol will improve the event-free survival, a measure integrating unfavorable events such as death, disease progression and treatment complications, particularly infections, in the low risk-group compared to the results of the PTLD-1 trial. In very high-risk patients data from the PTLD-1 and PTLD-1/3 trial have shown that the current treatment is not sufficient to control the disease. Death due to disease progression was observed in more than 80% of patients. Here, rituximab combined with alternating chemotherapy cycles of CHOP and DHAOx (+GCSF) may increase treatment efficacy with an acceptable toxicity profile.

In summary, the **PTLD-2** trials tests if the substitution of subcutaneous for intravenous rituximab and an updated stratification strategy that deescalates treatment for those at low risk and escalates treatment for those at very high risk can further improve the overall efficacy and safety of PTLD therapy.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posttransplant Lymphoproliferative Disorder</td>
<td>Drug: Rituximab sc</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Drug: Rituximab sc consolidation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug: Rituximab sc combined with CHOP chemotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx</td>
<td></td>
</tr>
</tbody>
</table>
Official Title: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial
• Response after full treatment [Time Frame: three months]
• Duration of response [Time Frame: two years]
• Treatment-related mortality [Time Frame: three months]

Other Outcome Measures:
• Frequency of grade III and IV leucocytopenia and grade III and IV infections by treatment group [Time Frame: Two years]

Estimated Enrollment: 90
Actual Study Start Date: February 3, 2015
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)

### Arms

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Experimental: Low-risk</strong>&lt;br&gt;All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.</td>
<td><strong>Drug: Rituximab sc</strong>&lt;br&gt;All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m² infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22. <strong>Other Name:</strong> Mabthera sc&lt;br&gt;<strong>Drug:</strong> Rituximab sc consolidation&lt;br&gt;Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113. <strong>Other Names:</strong>&lt;br&gt;• Rituximab sc&lt;br&gt;• Mabthera sc</td>
</tr>
</tbody>
</table>
| **Experimental: High risk**<br>All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if they reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive rituximab sc combined with CHOP chemotherapy and rituximab sc. | **Drug: Rituximab sc**<br>All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m² infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22. **Other Name:** Mabthera sc<br>**Drug:** Rituximab sc combined with CHOP chemotherapy<br>Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at...
risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.

Experimental: Very high-risk
All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.

Drug: Rituximab sc
All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m² infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.

Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m², adriamycine IV 50 mg/m², vincristine IV 1.4mg/m² (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycle). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m², day 1) and cytarabine (ARA-C, 2x 1000 mg/m² at day 2) dexamethasone PO (40 mg/m², day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.

Other Names:
- Mabthera sc
- Cyclophosphamide
- Adriamycin
- Vincristin
- Prednisone
Eligibility

Ages Eligible for Study: 18 Years and older (Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- CD20-positive PTLD with or without EBV association, confirmed after biopsy or resection of tumor
- Measurable disease of > 2 cm in diameter and/or bone marrow involvement
- Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or a combination of the organ transplantations mentioned
- ECOG ≤ 2
- Clinically insufficient response to an upfront reduction of immunosuppression with or without antiviral therapy
- Age at least 18 years
- Not legally incapacitated
- Written informed consent from the trial subject has been obtained

Exclusion Criteria:

- Complete surgical extirpation of the tumor or irradiation of residual tumor masses
- Upfront treatment with rituximab or chemotherapy
- Known allergic reactions against foreign proteins
- Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol
- Meningeal and CNS involvement
- Known to be HIV-positive
- Pregnant women and nursing mothers
- Failure to use highly-effective contraceptive methods
- Persons held in an institution by legal or official order
- Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
- Life expectancy less than 6 weeks

**Contacts and Locations**

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02042391

**Contacts**

Contact: Ralf U Trappe, Dr. med.  +49 (0)421-6102-1481  r.trappe@diako-bremen.de

**Locations**

**Germany**

Uniklinik RWTH Aachen Klinik für Onkologie, Hämatologie und Stammzell-transplantation Med. Klinik Aachen, Germany, 52074

Charite Universität medizin Berlin Campus Mitte, Medizinische Klinik mit Schwerpunkt Hämatologie Berlin, Germany, 10117

Charité - Universitätsmedizin Berlin CCM Medizinische Klinik m. S. Nephrologie Berlin, Germany, 10117

Universitätsklinikum Bonn Med. Klinik III/ZIM Hämatologie/Onkologie Bonn, Germany, 53105

DIAKO Bremen gGmbH, Klinik für Hämatologie und Onkologie Bremen, Germany, 28239

Universitätsklinikum Erlangen Med. Klinik 5 Hämatologie und Intern. Onkologie Erlangen, Germany, 91054

Universitätsklinikum Essen Klinik für Hämatologie Essen, Germany, 45147

Malteser Krankenhaus St. Franziskus-Hospital Med. Klinik 1 Flensburg, Germany, 24939

Universitätsklinikum Frankfurt Med. Klinik III, Nephrologie Frankfurt/Main, Germany, 60590

Universitätsklinikum Gießen Med. Klinik IV Gießen, Germany, 35385

Universitätsmedizin Göttingen, Klinik für Hämatologie und medizinische Onkologie Göttingen, Germany, 37075

Nephrologisches Zenrtum Niedersachsen Hann-Münden, Germany, 34346

Medizinische Hochschule Hannover Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Hannover, Germany 30625

https://clinicaltrials.gov/ct2/show/NCT02042391?term=ptld2&rank=1  09.08.2017
Sponsors and Collaborators
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

Investigators
Principal Investigator: Ralf U Trappe, Dr. med.- DIAKO Bremen

More Information

Publications:


https://clinicaltrials.gov/ct2/show/NCT02042391?term=ptld2&rank=1
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD)